ProMIS Neurosciences Inc. 8-K

What Happened
ProMIS Neurosciences Inc. announced in an 8-K (filed May 20, 2026) that its stockholders approved an amendment to the company’s 2025 Stock Option and Incentive Plan at the 2026 Annual Meeting held on May 20, 2026. The amendment, previously approved by the Board, became effective upon shareholder approval and increases the number of Common Shares available for issuance under the 2025 Plan by 900,000 shares. The amendment is described in Proposal 3 of the company’s Definitive Proxy Statement (filed April 9, 2026) and is filed as Exhibit 10.1 to the 8-K.

Key Details

• Amendment increases the 2025 Stock Option and Incentive Plan reserve by 900,000 Common Shares.
• Approval occurred at the Annual Meeting on May 20, 2026; the Board had previously approved the amendment.
• The Proxy Statement (Schedule 14A) describing the amendment was filed April 9, 2026; the amendment text is Exhibit 10.1 to the 8-K.
• The 8-K was signed by CEO Neil Warma on May 20, 2026.

Why It Matters
Increasing the number of shares available under the stock option and incentive plan provides the company with capacity to grant additional equity awards to employees, executives, and directors, which can be used for recruitment and retention. For investors, the key factual impacts are a larger potential pool of equity awards (which can cause dilution when exercised or vested) and a signal that the company plans to continue using equity compensation. The filing documents (Proxy Statement and Exhibit 10.1) contain the full terms and should be reviewed for details on grant mechanics and any limits.